LON:CREOCreo Medical Group Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Creo Medical Group PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 145 +2.50 (+1.75 %) (As of 05/26/2020 06:03 AM ET) Add Compare Share Today's Range 142.60Now: GBX 145▼ 14550-Day Range 105MA: GBX 129.28▼ 142.5052-Week Range 96Now: GBX 145▼ 211.17Volume952 shsAverage Volume16,051 shsMarket Capitalization£228.40 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Creo Medical Limited develops and sells instruments for surgical endoscopy in the United Kingdom. The company is developing instruments for endoscopy through a combination of bipolar radiofrequency and microwave energy in a single platform for tissue dissection, resection, ablation, and coagulation. It offers Speedboat RS2 instrument for endoscopic submucosal dissection. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was founded in 2003 and is based in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Creo Medical Group. Previous Next 2.5 Community Rank Outperform VotesCreo Medical Group has received 105 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCreo Medical Group has received 103 “underperform” votes. (Add your “underperform” vote.)Community SentimentCreo Medical Group has received 50.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Creo Medical Group and other stocks. Vote “Outperform” if you believe CREO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CREO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCreo Medical Group does not currently pay a dividend.Dividend GrowthCreo Medical Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Creo Medical Group insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Creo Medical Group is -11.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Creo Medical Group is -11.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCreo Medical Group has a P/B Ratio of 4.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolLON:CREO Previous Symbol CUSIPN/A CIKN/A Webcreomedical.com Phone+44-1291-606005Debt Debt-to-Equity Ratio2.00 Current Ratio9.50 Quick Ratio9.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£7,699.00 Price / Sales29,666.71 Cash FlowGBX 32.47 per share Price / Cash Flow4.47 Book ValueGBX 33.40 per share Price / Book4.34Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees50 Outstanding Shares157,520,000Market Cap£228.40 million Next Earnings DateN/A OptionableNot Optionable LSE:CREO Rates by TradingView Receive CREO News and Ratings via Email Sign-up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter. Creo Medical Group (LON:CREO) Frequently Asked Questions How has Creo Medical Group's stock been impacted by COVID-19 (Coronavirus)? Creo Medical Group's stock was trading at GBX 143.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CREO stock has increased by 1.0% and is now trading at GBX 145. View which stocks have been most impacted by Coronavirus. How were Creo Medical Group's earnings last quarter? Creo Medical Group PLC (LON:CREO) announced its quarterly earnings data on Tuesday, March, 20th. The company reported ($5.00) EPS for the quarter. View Creo Medical Group's earnings history. Has Creo Medical Group been receiving favorable news coverage? Press coverage about CREO stock has been trending very negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Creo Medical Group earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutCreo Medical Group. Who are some of Creo Medical Group's key competitors? Some companies that are related to Creo Medical Group include Zynex (ZYXI), Draegerwerk AG & Co KGaA (DRW3), Avacta Group (AVCT), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Hamilton Thorne (HTL), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Advanced Oncotherapy (AVO), Somnomed (SOM), Resonance Health (RHT), Kromek Group (KMK) and REVA Medical (RVA). View all competitors. What other stocks do shareholders of Creo Medical Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Creo Medical Group investors own include Mysquare (MYSQ) and IQE (IQE). Who are Creo Medical Group's key executives? Creo Medical Group's management team includes the following people: Mr. Craig Jonathan Gulliford, CEO & Director (Age 48)Prof. Christopher Paul Hancock, Founder, CTO & Director (Age 51)Mr. Richard John Rees ACA, CFO, Company Sec. & Director (Age 42)Mr. Phil Hales, Sales & Marketing Director What is Creo Medical Group's stock symbol? Creo Medical Group trades on the London Stock Exchange (LON) under the ticker symbol "CREO." How do I buy shares of Creo Medical Group? Shares of CREO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Creo Medical Group's stock price today? One share of CREO stock can currently be purchased for approximately GBX 145. How big of a company is Creo Medical Group? Creo Medical Group has a market capitalization of £228.40 million and generates £7,699.00 in revenue each year. Creo Medical Group employs 50 workers across the globe. What is Creo Medical Group's official website? The official website for Creo Medical Group is creomedical.com. How can I contact Creo Medical Group? The company can be reached via phone at +44-1291-606005. This page was last updated on 5/26/2020 by MarketBeat.com Staff
